Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

2015377 citationsJournal Articlebronze Open Access

Authors

Tadeusz Robak · Copernicus Memorial Hospital

Huiqiang Huang · Sun Yat-sen University Cancer Center

Jie Jin · First Affiliated Hospital Zhejiang University

Jun Zhu · Peking University Cancer Hospital

Ting Liu · Sichuan University

Olga Samoilova · Nizhny Novgorod Regional Clinical Hospital named after Semashko

Halyna Pylypenko

Abstract

VR-CAP was more effective than R-CHOP in patients with newly diagnosed mantle-cell lymphoma but at the cost of increased hematologic toxicity. (Funded by Janssen Research and Development and Millennium Pharmaceuticals; LYM-3002 ClinicalTrials.gov number, NCT00722137.).

Topics & Keywords

Lymphoma Diagnosis and Treatment Viral-associated cancers and disorders Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 372, Issue 10, pp. 944-953

DOI: 10.1056/nejmoa1412096

Field-Weighted Citation Impact: 37.89